Erythropoietin in Friedreich ataxia

Journal of Neurochemistry

Volumn 126, Issue SUPPL.1, 2013, Pages 80-87

  Mariotti, Caterina ^a   Nachbauer, Wolfgang ^b   Panzeri, Marta ^a   Poewe, Werner ^b   Taroni, Franco ^a   Boesch, Sylvia ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

erythropoietin; Friedreich ataxia

Indexed keywords

CARBAMYLATED ERYTHROPOIETIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FRATAXIN; GLUTAMIC ACID; HISTONE DEACETYLASE INHIBITOR; IDEBENONE; IRON; JANUS KINASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; REACTIVE OXYGEN METABOLITE; RECOMBINANT CYTOKINE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

APOPTOSIS; CARDIOVASCULAR DISEASE; CELL SURVIVAL; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; FLU LIKE SYNDROME; FRIEDREICH ATAXIA; HEART PROTECTION; HEMOSIDEROSIS; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE PRURITUS; MYALGIA; NAUSEA; NEUROPATHOLOGY; NEUROPROTECTION; NIGHT SWEAT; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PURE RED CELL ANEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; THROMBOSIS;

ERYTHROPOIETIN; FRIEDREICH ATAXIA;

ANIMALS; ERYTHROPOIETIN; FRIEDREICH ATAXIA; HUMANS; IRON-BINDING PROTEINS; RECOMBINANT PROTEINS;

EID: 84880388935     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12301     Document Type: Review

References (57)

1. Acquaviva F., Castaldo I., Filla A., Giacchetti M., Marmolino D., Monticelli A., Pinelli M., Sacca F., and, Cocozza S., (2008) Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 7, 360-365.
2. Adinolfi S., Iannuzzi C., Prischi F., Pastore C., Iametti S., Martin S. R., Bonomi F., and, Pastore A., (2009) Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS. Nat. Struct. Mol. Biol. 16, 390-396.
3. Boesch S., Sturm B., Hering S., Goldenberg H., Poewe W., and, Scheiber-Mojdehkar B., (2007) Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann. Neurol. 62, 521-524.
4. Boesch S., Sturm B., Hering S., Scheiber-Mojdehkar B., Steinkellner H., Goldenberg H., and, Poewe W., (2008) Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov. Disord. 23, 1940-1944.
5. Bogoyevitch M. A., (2004) An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc. Res. 63, 208-216.
6. Brines M., and, Cerami A., (2008) Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J. Intern. Med. 264, 405-432.
7. Brines M. L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N. C., Cerami C., Itri L. M., and, Cerami A., (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. USA 97, 10526-10531.
8. Bulteau A. L., O'Neill H. A., Kennedy M. C., Ikeda-Saito M., Isaya G., and, Szweda L. I., (2004) Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305, 242-245.
9. Burk K., Malzig U., Wolf S., et al,. (2009) Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov. Disord. 24, 1779-1784.
10. Calapai G., Marciano M. C., Corica F., Allegra A., Parisi A., Frisina N., Caputi A. P., and, Buemi M., (2000) Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur. J. Pharmacol. 401, 349-356.
11. Campuzano V., Montermini L., Molto M. D., et al,. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427.
12. Campuzano V., Montermini L., Lutz Y., et al,. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6, 1771-1780.
13. Casadevall N., (2003) Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol. Dial. Transplant. 18 (Suppl 8), viii37-viii41.
14. Chateauvieux S., Grigorakaki C., Morceau F., Dicato M., and, Diederich M., (2011) Erythropoietin, erythropoiesis and beyond. Biochem. Pharmacol. 82, 1291-1303.
15. Cheung W. K., Goon B. L., Guilfoyle M. C., and, Wacholtz M. C., (1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin. Pharmacol. Ther. 64, 412-423.
16. Deutsch E. C., Santani A. B., Perlman S. L., Farmer J. M., Stolle C. A., Marusich M. F., and, Lynch D. R., (2010) A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol. Genet. Metab. 101, 238-245.
17. Ehrenreich H., Hasselblatt M., Dembowski C., et al,. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8, 495-505.
18. Ehrenreich H., Hinze-Selch D., Stawicki S., et al,. (2007) Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol. Psychiatry 12, 206-220.
19. Ehrenreich H., Weissenborn K., Prange H., et al,. (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40, e647-e656.
20. Gao D., Ning N., Niu X., Dang Y., Dong X., Wei J., and, Zhu C., (2012) Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am. Heart J. 164 (715-727), e711.
21. Gerber J., Muhlenhoff U., and, Lill R., (2003) An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep. 4, 906-911.
22. Ghezzi P., Bernaudin M., Bianchi R., et al,. (2010) Erythropoietin: not just about erythropoiesis. Lancet 375, 2142.
23. He Y., Alam S. L., Proteasa S. V., Zhang Y., Lesuisse E., Dancis A., and, Stemmler T. L., (2004) Yeast frataxin solution structure, iron binding, and ferrochelatase interaction. Biochemistry 43, 16254-16262.
24. Juul S., (2002) Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr. Suppl. 91, 36-42.
25. Kawakami M., Sekiguchi M., Sato K., Kozaki S., and, Takahashi M., (2001) Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 276, 39469-39475.
26. Layer G., Ollagnier-de Choudens S., Sanakis Y., and, Fontecave M., (2006) Iron-sulfur cluster biosynthesis: characterization of Escherichia coli CYaY as an iron donor for the assembly of [2Fe-2S] clusters in the scaffold IscU. J. Biol. Chem. 281, 16256-16263.
27. Leidgens S., De Smet S., and, Foury F., (2010) Frataxin interacts with Isu1 through a conserved tryptophan in its beta-sheet. Hum. Mol. Genet. 19, 276-286.
28. Leist M., Ghezzi P., Grasso G., et al,. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305, 239-242.
29. Li F., Chong Z. Z., and, Maiese K., (2004) Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 13, 265-289.
30. Li H., Gakh O., Smith D. Y., and, t. and Isaya G., (2009) Oligomeric yeast frataxin drives assembly of core machinery for mitochondrial iron-sulfur cluster synthesis. J. Biol. Chem. 284, 21971-21980.
31. Macdougall I. C., Roger S. D., de Francisco A., et al,. (2012) Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 81, 727-732.
32. Mariotti C., Fancellu R., Caldarazzo S., et al,. (2012) Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov. Disord. 27, 446-449.
33. Nachbauer W., Hering S., Seifert M., et al,. (2011a) Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia-a dose-response trial. Cerebellum 10, 763-769.
34. Nachbauer W., Wanschitz J., Steinkellner H., et al,. (2011b) Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Mov. Disord. 26, 1935-1938.
35. Nachbauer W., Boesch S., Reindl M., Eigentler A., Hufler K., Poewe W., Loscher W., and, Wanschitz J., (2012) Skeletal muscle involvement in friedreich ataxia and potential effects of recombinant human erythropoietin administration on muscle regeneration and neovascularization. J. Neuropathol. Exp. Neurol. 71, 708-715.
36. O'Neill H. A., Gakh O., Park S., Cui J., Mooney S. M., Sampson M., Ferreira G. C., and, Isaya G., (2005) Assembly of human frataxin is a mechanism for detoxifying redox-active iron. Biochemistry 44, 537-545.
37. Pianese L., Turano M., Lo Casale M. S., De Biase I., Giacchetti M., Monticelli A., Criscuolo C., Filla A., and, Cocozza S., (2004) Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J. Neurol. Neurosurg. Psychiatry 75, 1061-1063.
38. Sacca F., Piro R., De Michele G., et al,. (2011a) Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Mov. Disord. 26, 739-742.
39. Sacca F., Puorro G., Antenora A., et al,. (2011b) A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS ONE 6, e17627.
40. Schmitz-Hubsch T., du Montcel S. T., Baliko L., et al,. (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66, 1717-1720.
41. Schulz J. B., Dehmer T., Schols L., et al,. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55, 1719-1721.
42. Shan Y., Napoli E., and, Cortopassi G., (2007) Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum. Mol. Genet. 16, 929-941.
43. Shingo T., Sorokan S. T., Shimazaki T., and, Weiss S., (2001) Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J. Neurosci. 21, 9733-9743.
44. Siren A. L., and, Ehrenreich H., (2001) Erythropoietin-a novel concept for neuroprotection. Eur. Arch. Psychiatry Clin. Neurosci. 251, 179-184.
45. Siren A. L., Fasshauer T., Bartels C., and, Ehrenreich H., (2009) Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6, 108-127.
46. Steinkellner H., Scheiber-Mojdehkar B., Goldenberg H., and, Sturm B., (2010) A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels. Anal. Chim. Acta 659, 129-132.
47. Sturm B., Stupphann D., Kaun C., Boesch S., Schranzhofer M., Wojta J., Goldenberg H., and, Scheiber-Mojdehkar B., (2005) Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur. J. Clin. Invest. 35, 711-717.
48. Sturm B., Helminger M., Steinkellner H., Heidari M. M., Goldenberg H., and, Scheiber-Mojdehkar B., (2010) Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur. J. Clin. Invest. 40, 561-565.
49. Subramony S. H., May W., Lynch D., Gomez C., Fischbeck K., Hallett M., Taylor P., Wilson R., and, Ashizawa T., (2005) Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64, 1261-1262.
50. Tan C. C., Eckardt K. U., Firth J. D., and, Ratcliffe P. J., (1992) Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am. J. Physiol. 263, F474-F481.
51. Tan G., Chen L. S., Lonnerdal B., Gellera C., Taroni F. A., and, Cortopassi G. A., (2001) Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum. Mol. Genet. 10, 2099-2107.
52. Taroni F., and, DiDonato S., (2004) Pathways to motor incoordination: the inherited ataxias. Nat. Rev. Neurosci. 5, 641-655.
53. Tonia T., Mettler A., Robert N., Schwarzer G., Seidenfeld J., Weingart O., Hyde C., Engert A., and, Bohlius J., (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev. 12, CD003407.
54. Wang T., and, Craig E. A., (2008) Binding of yeast frataxin to the scaffold for Fe-S cluster biogenesis, Isu. J. Biol. Chem. 283, 12674-12679.
55. Willis J. H., Isaya G., Gakh O., Capaldi R. A., and, Marusich M. F., (2008) Lateral-flow immunoassay for the frataxin protein in Friedreich's ataxia patients and carriers. Mol. Genet. Metab. 94, 491-497.
56. Yoon T., and, Cowan J. A., (2003) Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J. Am. Chem. Soc. 125, 6078-6084.
57. Yoon T., and, Cowan J. A., (2004) Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biol. Chem. 279, 25943-25946.